Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Related articles in Annals
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Aster, R. H.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

EDITORIAL

Quinine Sensitivity: A New Cause of the Hemolytic Uremic Syndrome

right arrow Richard H. Aster

1 August 1993 | Volume 119 Issue 3 | Pages 243-244


In this issue of Annals, Maguire and coworkers [1] describe two patients who had symptoms and laboratory findings consistent with the adult hemolytic uremic syndrome of acute onset. In addition to the expected findings of microangiopathic hemolytic anemia, thrombocytopenia, and renal failure, both patients had neutropenia and low-grade disseminated intravascular coagulation. One patient had a similar episode about 2 years earlier, and the other reported many previous episodes. The initial histories that the patients gave failed to identify exposure to medications. However, the urine of one patient contained quinine, the probable source of which was tonic water, and circumstantial evidence suggested that the second patient had taken quinine to prevent nocturnal leg cramps. Quinine was also implicated by the finding of quinine-dependent antibodies reactive with platelets, granulocytes, and erythrocytes in the serum of both patients. Clearly these patients had quinine-induced hemolytic uremic syndrome, a recently described syndrome [2] that can occur with or without associated disseminated intravascular coagulation or granulocytopenia [3, 4].

Many mechanisms have been implicated in drug-induced blood dyscrasias and tissue damage [5]. When peripheral destruction of cellular elements of the blood occurs, the cause is usually a peculiar type of immunoglobulin that, although harmless in itself, binds avidly to certain glycoproteins expressed on blood cells in the presence of the sensitizing drug [6]. Hundreds of drugs can induce such antibodies, but quinine and its diastereoisomer, quinidine, appear to do so more often than other agents. Only a small percentage of patients taking quinidine and quinine have this sensitivity, and there is no way to identify susceptible individuals. Although platelets are the preferred target for drug-induced antibodies, granulocytes, erythrocytes, and probably other tissues [7-9] are sometimes affected. Patients usually recover spontaneously when the provocative drug is withdrawn.

The mechanism by which drugs promote selective binding of these immunoglobulins to target glycoproteins is not fully understood, but evidence suggests that the inciting medications bind reversibly to specific protein domains to form complexes or to induce conformational changes ("neoantigens") for which the antibodies are specific [5, 10, 11]. Why acute renal failure should develop in some patients with quinine-induced antibodies is unclear because intravascular hemolysis is generally not severe. Stroncek and colleagues [4] have suggested that the binding of immunoglobulins to granulocytes causes them to adhere to the microvasculature of the kidneys to produce renal dysfunction. Neahring and coworkers [12] have identified immunoglobulin (Ig)G and IgM antibodies reactive with endothelial cells in patients with quinine-induced hemolytic uremic syndrome and have suggested that antibody-mediated injury to endothelium may be responsible.

Maguire and associates raise several important points: Drug sensitivity should be suspected in any adult with acute-onset hemolytic uremic syndrome or thrombotic thrombocytopenic purpura, especially when associated with renal insufficiency. From the cases described in their article, it is apparent that this holds true even when the patient has no history of drug exposure. In my own clinical experience, I have found it remarkable how often patients with drug-induced thrombocytopenia deny drug exposure, especially during the acute phase of their illness. With respect to quinine, clinicians should keep in mind that this drug is present in soft drinks, aperitifs, and various over-the-counter medications and that sensitivity reactions can be induced by quinine in each of these forms.

The authors also raise the question of whether quinine in tablet form should be dispensed by prescription only. The most common use of quinine in tablet form is for the prevention of nocturnal muscle cramps, which can be distressing to susceptible individuals, especially the elderly. In the past, it has been questioned whether quinine is even effective for this purpose. Several recent clinical trials, however, have shown that the drug does, in fact, substantially reduce the frequency of such symptoms [13-16]. It can therefore be argued that quinine should remain available for this therapeutic indication. Limiting quinine tablets to prescription would, of course, not influence the exposure of millions of persons annually to quinine contained in beverages. The latter exposure is undoubtedly much more common than exposure to quinine in tablet form.

Most severe quinine side effects appear to be associated with ingestion of quinine tablets. This suggests that the larger dose of quinine contained in tablets (about 250 mg) is more likely to induce sensitivity, or at least to produce serious consequences, than the smaller amounts contained in, for example, tonic water (about 15 mg per bottle). Unfortunately, no animal model of drug sensitivity is available in which to study dose-response relationships in the induction of quinine sensitivity. Given that quinine is widely available to the public, studies to determine the frequency with which this compound causes substantial side effects seem to be indicated.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowReferences

Medical College of Wisconsin, Milwaukee, WI 53233.
Requests for Reprints: Richard H. Aster, MD, The Blood Center, 1701 West Wisconsin Avenue, Milwaukee, WI 53233.
Grant Support: By grant HL13621 from the National Heart, Lung, and Blood Institute.


References
space
up arrowTop
up arrowAuthor & Article Info
dotReferences

1. Maguire RB, Stroncek DF, Campbell AC. Recurrent pancytopenia, coagulopathy, and renal failure associated with multiple quinine-dependent antibodies. Ann Intern Med. 1993; 119:215-7.

2. Gottschall JL, Elliot W, Lianos E, McFarland JG, Wolfmeyer K, Aster RH. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity. Blood. 1991; 77:306-10.

3. Spearing RL, Hickton CM, Sizeland P, Hannah A, Bailey RR. Quinine-induced disseminated intravascular coagulation. Lancet. 1990; 336:1535-7.

4. Stroncek DF, Vercellotti GM, Hammerschmidt DE, Christie DJ, Shankar RA, Jacob JS. Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. Blood. 1992; 80:241-8.

5. Salama A, Mueller-Eckhardt C. Immune-mediated blood cell dyscrasias related to drugs. Semin Hematol. 1992; 29:54-63.

6. Aster RH, George JN. Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA; eds. Hematology. 4th ed. New York: McGraw-Hill; 1990:1370-97.

7. Calloway JL, Tate WE. Toxic epidermal necrolysis caused by "gin and tonic" (Letter). Arch Dermatol. 1974; 109:909.

8. Sukenik S, Horowitz J, Katz A, Henkin J, Buskila D. Quinidine-induced lupus erythematosus-like syndrome: three case reports and a review of the literature. Isr J Med Sci. 1987; 23:1232-4.

9. Alam M, Duvernoy WF, Pickard SD, Aronsohn PL. Quinidine-induced hepatitis and thrombocytopenia. Henry Ford Hosp Med J. 1987; 25:53-6.

10. Christie DJ, Aster RH. Drug-antibody-platelet interaction in quinine- and quinidine-induced thrombocytopenia. J Clin Invest. 1982; 70: 989-98.

11. Chong BH. Drug-induced immune thrombocytopenia. Platelets. 1991; 2:173-81.

12. Neahring BJ, Scott JP, Visentin GP, Gottschall JL, Aster RH. Quinine-dependent anti-endothelial cell antibodies in plasma of patients with hemolytic-uremic syndrome (HUS). Proceeding of the 14th Congress of International Society of Thrombosis and Hemostasis. 1993; (In press).

13. Jones K, Castleden CM. A double-blind comparison of quinine sulphate and placebo in muscle cramps. Age Ageing. 1983; 12:155-8.

14. Fung MC, Holbrook JH. Placebo-controlled trial of quinine therapy for nocturnal leg cramps. Western J Med. 1989; 151:42-4.

15. Gorlich HD, Gablenz EV, Steinberg HW. Behandlung rezidivierender nachtlicher Wadenkrampfe. Eine multizentrische, doppelblinde, plazebo-kontrollierte vergleichsuntersuchung zwischen der kombination von chinin und theophyllin-ethylendiamin gegenuber chinin. Drug Res. 1991; 41:167-75.

16. Connolly PS, Shirley EA, Wasson JH, Nierenberg DW. Treatment of nocturnal leg cramps. A crossover trial of quinine vs vitamin E. Arch Intern Med. 1992; 152:1877-80.

Related articles in Annals:

Brief Reports
Recurrent Pancytopenia, Coagulopathy, and Renal Failure Associated with Multiple Quinine-dependent Antibodies
Robert B. Maguire, David F. Stroncek, AND Allan C. Campbell
Annals 1993 119: 215-217. [Full Text]  



This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
G. Rabetoy, M. Hansen, G. Brosnahan, and L. Hartung
The lady who had muscle cramps and developed thrombotic microangiopathy
Nephrol. Dial. Transplant., September 1, 2000; 15(9): 1464 - 1467.
[Full Text] [PDF]


box Article
 arrow  Table of Contents                
space
 arrow  Related articles in Annals
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Aster, R. H.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online